Table of Contents
SCHIZOPHRENIA
- EXECUTIVE SUMMARY
- THE FACTS
- What is schizophrenia and why are we interested in it?
- Symptoms associated with schizophrenia
- Schematic depicting mood swings in bipolar disorder
- PATIENT STATISTICS
- Incidence, diagnosis rates and treatment; now and in the future
- PATIENT MODEL
- Summary of patient population forecasts 2005A-2012E
- DRUG GROWTH DRIVERS
- DRUG GROWTH RISKS/DAMPENERS
GLOBAL SCHIZOPHRENIA MARKET
- Global CNS Market (US$68.7 billion)
- GLOBAL SALES SPLIT
- Global sales split (2005A)
- Prescription usage split (2005A)
- The major players
- Market share of antipsychotic players by sales (Dec 2005A)
- Market share of antipsychotic players by sales (Dec 2006E)
- Players and Products in 2005 & 2006
- Players and Products in 2012
- Market share of antipsychotic players by sales (Dec 2012E)
- CURRENT TREATMENTS
- Leading Brands
- Comparison of leading antipsychotic drugs
- Current Products Patent Exposure
- Patent Exposure of Leading Antipsychotic Brands
- ANALYSIS OF LEADING BRANDS
- Atypical antipsychotics
- Other Agents
- ATYPICAL ANTIPSYCHOTICS
- Abilify (Bristol-Myers Squibb/Otsuka)
- Geodon/Zeldox (Pfizer)
- Risperdal (Johnson & Johnson)
- Seroquel (AstraZeneca)
- Zyprexa (Eli Lilly)
- Other atypical antipsychotics:
- Serdolect (Lundbeck)
- Lullan
- Clozaril/Leponex (Novartis)
- Solian (sanofi-aventis)
- GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2005 - 2012
- Sales Forecasts of Current Leading Antipsychotics
- Model assumptions
- NEW DRUGS IN R&D
- Drugs in Development to Treat Schizophrenia and Bipolar Disorder
- ANALYSIS OF PHASE III DRUGS
- Drugs in Phase III Development to Treat Schizophrenia and Bipolar
Disorder
- D/5-HT receptor antagonists
- D/5-HT receptor antagonists
- Asenapine (Pfizer/Organon)
- Bifeprunox (Wyeth/Solvay/Lundbeck)
- Blonanserin (Dainippon Sumitomo)
- Clinical Efficacy of Blonanserin
- Iloperidone (Vanda Pharmaceutical)
- Safety Profile of Iloperidone vs. Approved Antipsychotics
- Paliperidone (Johnson & Johnson)
- GLOBAL SALES FORECASTS OF PHASE III SCHIZOPHRENIA DRUGS 2006 - 2012
- Sales Forecasts of Phase III Developmental Antipsychotic Drugs
- Model assumptions
- ANALYSIS OF PHASE II DRUGS
- New Drugs in Early Clinical Development to Treat Schizophrenia/Bipolar
Disorder
- Lurasidone (Dainippon Sumitomo/Merck & Co.)
- Ocaperidone (Neuro3d)
- SGS518 (Eli Lilly/Saegis Pharmaceuticals)
- Talnetant (GlaxoSmithKline)
- Talnetant Efficacy and Safety Profile
- Talnetant Cognitive Effects
- ABT-089 (Abbott)
- ORG 24448 (Akzo Nobel/Cortex Pharmaceuticals)
- Vabicaserin (Wyeth)
- GLOBAL SALES FORECASTS OF PHASE II ANTIPSYCHOTIC DRUGS 2005-2012
- Sales Forecasts of Phase II Developmental Antipsychotic Drugs
- Model assumptions
- COMPETITOR RATIO ANALYSIS
- CR Analysis of Antipsychotic Agents Approved by 2012 - Based on Drug
Class
- COMPETITOR RATIO ANALYSIS - COMPANIES
- CR Analysis of Antipsychotics Approved by 2012 - Based on Company
- WINNERS & LOSERS
- Summary of Key Companies and Drugs in the Antipsychotic Market by 2012
- Winners
- Losers
- DISCONTINUATION OF DRUGS
- Antipsychotic Drugs Discontinued from Clinical Development
- SCHIZOPHRENIA APPENDIX 1
- Assessment of antipsychotic efficacy in schizophrenia
- Assessment of antipsychotic efficacy in bipolar disorder
- SCHIZOPHRENIA APPENDIX 2
- Phase transition probability
- SCHIZOPHRENIA APPENDIX 3
- Patient Model
- Summary of US Schizophrenia Patient Population Forecasts
- Summary of European (Top 5) Schizophrenia Patient Population Forecasts
- Summary of Japanese Schizophrenia Patient Population Forecasts
- SCHIZOPHRENIA APPENDIX 4
- Global Antipsychotic Drug Sales 2005A-2012E
- SCHIZOPHRENIA APPENDIX 5
- Competitor Ratio Analysis Criteria
- Key Antipsychotic Drugs on the Market by 2012
- SCHIZOPHRENIA GLOSSARY
- SCHIZOPHRENIA REFERENCES
- ACRONYMS
|
Related Report
|
View Cart
